Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid
- 9 January 2023
- journal article
- research article
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 46 (9) , 692-701
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81820108005, 81900502, 82173241)
- National Key Research and Development Program of China (2017YFA0105704)
- Key Research and Development Projects of Shaanxi Province (2021ZDLSF02-07)
This publication has 30 references indexed in Scilit:
- Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up StudyGastroenterology, 2014
- Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta‐analysisHepatology Research, 2014
- Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acidAlimentary Pharmacology & Therapeutics, 2010
- Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2009
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisHepatology, 2008
- Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2006
- Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary CirrhosisHepatology, 1999
- Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor α-dependent pathwayToxicology Letters, 1998
- Prognosis in primary biliary cirrhosis: Model for decision makingHepatology, 1989
- Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)Virchows Archiv, 1978